ODM 108

Drug Profile

ODM 108

Alternative Names: ODM-108

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Orion
  • Class Analgesics
  • Mechanism of Action TRPA1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 16 Aug 2016 Orion Corporation terminates the phase I FIMTRIP trial (In volunteers) in the Netherlands after August 2016(NCT02432664)
  • 19 Jul 2016 Discontinued - Phase-I for Neuropathic pain in Netherlands (PO) because of findings concerning tolerability of ODM 108
  • 29 Apr 2015 Phase-I clinical trials in Neuropathic pain (In volunteers) in Netherlands (PO) (NCT02432664)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top